A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology

Journal of Medical Genetics

Volumn 40, Issue 10, 2003, Pages 787-792

  Giusti, R M ^a   Rutter, J L ^a   Duray, P H ^a   Freedman, L S ^b   Konichezky, M ^c   Fisher Fischbein, J ^d   Greene, M H ^a   Maslansky, B ^d   Fischbein, A ^e   Gruber, S B ^f   Rennert, G ^g   Ronchetti, R D ^a   Hewitt, S M ^a   Struewing, J P ^a   Iscovich, J ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d International Fertility Institute   (Israel)

^e Selikoff Center for Environmental Health and Human Development   (Israel)

^f UNIVERSITY OF MICHIGAN   (United States)

^g CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PARAFFIN;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; ETHNOLOGY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOLOGY; HISTOPATHOLOGY; HOSPITAL; HUMAN; HUMAN TISSUE; JEW; LABORATORY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; RISK ASSESSMENT; SCORING SYSTEM;

EID: 0142209176     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.40.10.787     Document Type: Article

References (14)

1. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
2. Foulkes WD, Brunet JS, Warner E, Goodwin PJ, Meschino W, Narod SA, Goss PE, Glendon G. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7.
3. Hubert A, Peretz T, Manor O, Kaduri L, Wienberg N, Lerer I, Sagi M, Abeliovich D. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999;65:921-4.
4. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998;78:771-3.
5. Nastiuk KL, Mansukhani M, Terry MB, Kularatne P, Rubin MA, Melamed J, Gammon MD, Ittmann M, Krolewski JJ. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999;40:172-7.
6. Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T, Livne PM, Friedman E. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 2000;83:463-6.
7. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-14.
8. Bahar AY, Taylor PJ, Andrews L, Proos A, Burnett L, Tucker K, Friedlander M, Buckley MF. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Cancer 2001;92:440-5.
9. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, Walther MM, Choyke P, Linehan WM, Zbar B. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999;155:517-26.
10. Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM. Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol 1999;162:1246-58.
11. Gruber SB, Ellis NA, Scott KK, Almog R, Kolachana P, Bonner JD, Kirchhoff T, Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rapaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Offit K. BLM heterozygosity and the risk of colorectal cancer. Science 2002;297:2013.
12. Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 1999;65:1800-2.
13. Cuzick J. A method for analysing case-control studies with ordinal exposure variables. Biometrics 1985;41:609-21.
14. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.